306 related articles for article (PubMed ID: 16015036)
1. The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M; Sobrero A; Gasparini G; Berardi R; Catalano V; Graziano F; Barni S; Zaniboni A; Beretta GD; Labianca R; Cascinu S;
Oncology; 2005; 68(2-3):212-6. PubMed ID: 16015036
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.
Bécouarn Y; Senesse P; Thézenas S; Boucher E; Adenis A; Cany L; Jacob JH; Cvitkovic F; Montoto-Grillot C; Ychou M;
Ann Oncol; 2007 Dec; 18(12):2000-5. PubMed ID: 17785765
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Fisher MD
Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
[No Abstract] [Full Text] [Related]
5. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
Wasserman E; Sutherland W; Cvitkovic E
Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
[TBL] [Abstract][Full Text] [Related]
8. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
10. Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Popov IP; Jelic SB; Matijasevic MM; Grbic B; Babic DR
J Exp Clin Cancer Res; 2004 Sep; 23(3):395-401. PubMed ID: 15595627
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
[TBL] [Abstract][Full Text] [Related]
12. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
13. Current approaches to first-line treatment of advanced colorectal cancer.
Goldberg RM
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S9-15. PubMed ID: 15212700
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
16. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
de Gramont A; Buyse M; Abrahantes JC; Burzykowski T; Quinaux E; Cervantes A; Figer A; Lledo G; Flesch M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; Tournigand C
J Clin Oncol; 2007 Aug; 25(22):3224-9. PubMed ID: 17664470
[TBL] [Abstract][Full Text] [Related]
17. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Kuebler JP; de Gramont A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer: integrating oxaliplatin.
Louvet C; de Gramont A
Curr Treat Options Oncol; 2003 Oct; 4(5):405-11. PubMed ID: 12941200
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
[TBL] [Abstract][Full Text] [Related]
20. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
